Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Cardiology

Journal Scan / Research · May 28, 2020

Lifetime Benefits of Comprehensive Disease-Modifying Pharmacological Therapies in Patients With HFrEF

The Lancet

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Estimating Lifetime Benefits of Comprehensive Disease-Modifying Pharmacological Therapies in Patients With Heart Failure With Reduced Ejection Fraction: A Comparative Analysis of Three Randomised Controlled Trials
Lancet 2020 May 21;[EPub Ahead of Print], M Vaduganathan, BL Claggett, PS Jhund, JW Cunningham, J Pedro Ferreira, F Zannad, M Packer, GC Fonarow, JJV McMurray, SD Solomon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading